Nisa Investment Advisors LLC Grows Position in Boston Scientific Corporation (NYSE:BSX)

Nisa Investment Advisors LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 405,955 shares of the medical equipment provider's stock after buying an additional 17,160 shares during the period. Nisa Investment Advisors LLC's holdings in Boston Scientific were worth $40,953,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of BSX. Bank Pictet & Cie Europe AG grew its holdings in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Boston Scientific by 18.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock worth $3,987,000 after purchasing an additional 6,264 shares during the period. Blue Trust Inc. lifted its position in shares of Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after purchasing an additional 575 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of Boston Scientific by 109.9% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock worth $24,126,000 after acquiring an additional 141,398 shares in the last quarter. Finally, Little House Capital LLC bought a new position in shares of Boston Scientific in the 1st quarter worth about $945,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 0.7%

Shares of BSX stock traded down $0.70 during trading hours on Friday, reaching $103.16. 5,890,147 shares of the stock were exchanged, compared to its average volume of 6,697,485. The business's fifty day moving average is $103.46 and its two-hundred day moving average is $100.45. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.53. The firm has a market capitalization of $152.62 billion, a P/E ratio of 75.30, a P/E/G ratio of 2.68 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm's quarterly revenue was up 20.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.56 earnings per share. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,314 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the sale, the executive vice president directly owned 22,235 shares of the company's stock, valued at $2,269,304.10. This trade represents a 43.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the sale, the senior vice president directly owned 36,193 shares of the company's stock, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 461,970 shares of company stock valued at $47,755,193. 0.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on BSX. BTIG Research reiterated a "buy" rating and issued a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, April 23rd. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Evercore ISI upped their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Finally, Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Twenty-two investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $116.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.